Space Station Bioprinting Experiment Advances Lab-Grown Tissues
Tuesday, 2026/07/14243 words4 minutes487 reads
San Diego-based Auxilium Biotechnologies has announced a significant milestone in space-based bioprinting, successfully creating structures containing human liver, kidney, and cartilage cells using its 3D bioprinter aboard the International Space Station. This achievement represents the first instance of liver and kidney tissues being bioprinted in the microgravity environment of space, with cells supplied by researchers at Wake Forest University.
The experiment specifically targeted a fundamental challenge in tissue engineering: achieving precise control over the spatial distribution of different cell types within three-dimensional structures. Terrestrial gravity causes particles and cells to sediment or aggregate unevenly, potentially compromising tissue functionality. Auxilium's hypothesis is that microgravity conditions enable cells and biomaterials to maintain more uniform distribution throughout the printed structure.
The bioprinter was deployed to the space station in 2024, with the initial objective of enhancing nerve-repair implants through more homogeneous distribution of drug-containing particles, thereby ensuring sustained exposure of regenerating nerves to therapeutic compounds. For this recent mission, the company transmitted bio-inks to orbit and remotely uploaded updated printer protocols while monitoring operations via station cameras. The fabricated liver and kidney structures returned to Earth approximately two weeks prior to this report for comprehensive analysis. While these constructs are not functional organs, researchers anticipate the field will initially focus on developing smaller tissue patches that could eventually facilitate the repair of damaged organs such as the liver. Medical products manufactured in space remain years from clinical application, and regulatory frameworks are only beginning to emerge.
